Stock Ratings / Health Care / FENC / insiders

AGMB (51) TRXB (49) ZURA (29) TECX (37) ⌘ Pro Terminal →

Fennec Pharmaceuticals Inc. (FENC) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$10.95 +0.74% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Fennec Pharmaceuticals Inc. (FENC) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $383.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-9.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FENC)Realized 20D OHLCV Swing Band: ±11.1%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

FENC Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (FENC)

No recent open-market Form 4 cluster sales or emergency dumps flagged on FENC. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FENC)

✓Walkthrough of FENC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

FENC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +68.72%▲ ASCENDING CHANNEL

2026-10-30O $10.89H $11.05L $10.14C $10.95VOL 195.7K

RES: $16.10SUP: $9.95SMA50: $10.93SMA200: $9.21

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FENC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 FENC Butterfly Map → + Track FENC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -6.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on FENC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for FENC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for FENC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FENC)

Health Care Rank #782 of 1016 ⚔️ AGMB vs FENC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (FENC vs. AGMB, TRXB, ZURA, TECX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Fennec Pharmaceuticals Inc. (FENC) ranks #782 by composite RQD confidence (36/100, grade D-) and #486 by equity capitalization ($383.6M). Within this direct 5-issuer industry benchmark cohort, FENC leads on earnings valuation at N/A trailing P/E, while FENC leads on capital efficiency and profitability with -25.9% ROIC and — gross margin. AGMB currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with FENC at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
FENC ACTIVE Fennec Pharmaceuticals Inc.	D-	36/100	—	—	-25.9%	+0.74%	$383.6M	Benchmark Subject
AGMB AgomAb Therapeutics NV	D	51/100	—	—	—	-0.13%	$391.5M	/agmb-vs-fenc →
TRXB TRex Bio Inc.	D	49/100	—	—	—	-6.31%	$371.1M	/trxb-vs-fenc →
ZURA Zura Bio Limited (Class A)	E	29/100	—	—	-35.0%	-11.49%	$370.9M	/zura-vs-fenc →
TECX Tectonic Therapeutic Inc.	D-	37/100	—	—	-35.0%	-0.29%	$400.8M	/tecx-vs-fenc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001211583

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Fennec Pharmaceuticals Inc. (FENC) reported GAAP revenue of $44.6M (-6.1% vs. FY2024 revenue of $47.5M , and +110.1% cumulative change since FY2023) , GAAP net income of -$9.74B, operating cash flow of -$12.5M, and free cash flow of -$12.5M (-146.2% YoY). On the balance sheet, FENC closed FY2025 with $70.6M in total assets against $0 in total debt (Altman Z-Score: 3.31, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$44.6M	-$9.74B	-$12.5M	-$12.5M	$70.6M	—
FY2024 (FY)	2024-12-31	$47.5M	-$436.0M	$27.0M	$27.0M	$44.9M	—
FY2023 (FY)	2023-12-31	$21.3M	-$16.05B	-$17.1M	-$17.1M	—	—

3. FENC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FENC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Fennec Pharmaceuticals Inc. (NASDAQ: FENC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $10.95 (+0.74% 1D, market cap $383.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, FENC ranks #782 in composite RQD confidence.

How does FENC compare to AGMB and TRXB in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), FENC carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -25.9%. By comparison, AGMB (AgomAb Therapeutics NV) holds a D grade (51/100 RQD, P/E N/A, ROIC —, cap $391.5M) and TRXB (TRex Bio Inc.) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $371.1M). Among the 5-stock peer group, FENC leads on earnings multiple (N/A) while FENC leads on capital efficiency (-25.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for FENC?

Per FENC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001211583), Fennec Pharmaceuticals Inc. generated $44.6M in revenue (-6.1% YoY), -$9.74B in net income, and -$12.5M in free cash flow against $70.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is FENC trading relative to its 50-day, 200-day, and 52-week technical levels?

FENC last traded at $10.95 (+0.74% on volume of 180,573 shares), positioning the stock +0.18% above its 50-day simple moving average ($10.93) and +18.89% above its 200-day simple moving average ($9.21). Across its 52-week range of $5.65 to $13.25, FENC sits at the 69.7% percentile with a 14-day RSI of 45.5 (NEUTRAL RANGE) and an implied next-earnings move of ±11.1% ($9.73 to $12.17).

FENC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are FENC insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies FENC leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: FENC RQD Cockpit FENC 12M Forecast FENC Earnings & Move FENC Dividends & DRIP FENC Insiders & 13F FENC Whale Options FENC Profit Sankey FENC News & Why